Remove privacy-policy
article thumbnail

MD Anderson and Xilis partner to expedite new cancer therapies development

Pharmaceutical Technology

It may offer opportunities for third-party collaborations to guide the new cell therapies and drugs development, if successful. It enables quick evaluation of a patient tumour response to a range of cancer drug modalities within 14 days of obtaining harvested samples of tumour cells.

article thumbnail

ACI To Host Multiple Events Featuring HP&M Speakers – Discounts Available to FDA Law Blog Readers

FDA Law Blog: Biosimilars

John counsels FDA-regulated entities on litigation, enforcement, and compliance matters including FDA inspections, Form 483s, Warning and Untitled Letters and Consent Decrees, internal investigations, and data privacy concerns. More information about the conference can be found here. FDA Law Blog readers can use discount code S10-866-866L24.S

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Forge Biologics and Labcorp partner for gene therapies development

Pharmaceutical Technology

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes.

article thumbnail

Twist rolls out TCR and CAR libraries for cell therapies development

Pharmaceutical Technology

Twist Bioscience CEO and co-founder Emily Leproust said: “With the dramatic increase in interest around cell and gene therapies, the addition of Twist CAR and TCR Libraries offers an important and differentiated tool to enable the development of the next generation of treatments for those suffering from a wide range of diseases.

article thumbnail

Solid Biosciences partners with Phlox for cardiac disease therapies

Pharmaceutical Technology

Under the research partnership deal, the companies will develop new precision genetic medicines for a severe form of genetic dilated cardiomyopathy (DCM). By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy.

article thumbnail

GenScript ProBio and CCS partner for cell and gene therapies development

Pharmaceutical Technology

These solutions will help drug developers address the challenges of regulatory compliance, production scalability, quality assurance and cost-effectiveness. The companies will offer a comprehensive suite of cell therapy services to biotech, pharmaceutical and government entities, and to hospitals.

article thumbnail

New UK intracellular drug delivery centre to support RNA development

Pharmaceutical Technology

Strathclyde Institute of Pharmacy and Biomedical Sciences head professor Yvonne Perrie said: “This centre will provide new capabilities for mRNA-based drug development and manufacture of cost-effective vaccines and therapeutics in the UK, boosting not only economic growth but also security of supply.”